VJHemOnc is committed to improving our service to you

COMy 2017 | What is induction therapy for autologous stem cell transplanation?

VJHemOnc is committed to improving our service to you

Michele Cavo

Michele Cavo, MD, from the Bologna University School of Medicine, Bologna, Italy, discusses current guidelines for induction therapy for autologous stem cell transplantation at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. The International Myeloma Working Group and the ESMO guidelines recommend a three-drug regimen including a proteasome inhibitor as the standard of care induction therapy for patients undergoing autologous stem cell transplantation. Lenalidomide is recommended as the standard of care maintenance therapy for this treatment.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter